АШУҮИС — Судалгааны мэдээлэл (CRIS)
Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001
Browse
2 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antiviral Efficacy and Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B(Mongolian National University of Medical Sciences, 2020-12-29); ;Amaraa Ravdan ;Gegeebadrakh Baljinnyam ;Burmaajav BadrakhObjectives: To provide compare of the efficacy and safety tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative and HBeAg-positive chronic hepatitis B. Methods: We performed a randomized, unblinded, non-inferiority study in which patients with compensated cirrhosis (Child-Pugh A and B stage) between 18-70 years old with a positive chronic hepatitis B test were randomized to receive either TAF, TDF, or were switched from TDF to TAF. The primary efficacy endpoint was the proportion of patients with HBV-DNA < 29 IU/ml at week 48. Results: The efficacy endpoint, an HBV-DNA < 29 IU/ ml at weeks 48, was achieved by 251 (79.9 %) of 314 patients receiving TAF, which was not significantly different from the 113 (74.8 %) of 151 patients receiving TDF. After 48 weeks of treatment, patients receiving TAF had significantly smaller bone mineral density reductions than patients receiving TDF. At week 48, the median decrease in eGFR was significantly less in the TAF recipients than the TDF recipients. Conclusion: TAF treatment has the same efficacy as TDF treatment. However, TAF treatment had a better safety profile than TDF. Patients receiving TAF had a significantly smaller median decrease in the eGFR by the Cockcroft-Gault equation than patients receiving TDF. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance(Wiley, 2017-02) ;Lee, S ;Ahn, S H ;Jung, K S ;Kim, D YKim, B KWe compared the viral suppressive efficacy of tenofovir disoproxil fumarate (TDF) mono-rescue therapy (TDF group) and TDF plus entecavir (ETV) combination-rescue therapy (TDF + ETV group) in chronic hepatitis B (CHB) patients with lamivudine resistance and entecavir resistance. One hundred and thirty-three CHB patients with lamivudine and entecavir resistance were investigated. Ninety-six patients were treated with TDF and 37 with TDF + ETV for at least 6 months. We compared the virologic response rate (HBV DNA level <20 IU/mL) between the two groups and identified the predictive factors of treatment outcome. There were no significant differences between the two groups in demographic characteristics. Up to 24 months [median: 18 (range 6-24) months], 85.4% and 89.2% of the TDF group and TDF + ETV group, respectively, achieved a virologic response (P=.068). Only the HBV DNA level at baseline was significantly associated with a virologic response in the multivariate analysis. In a subanalysis of patients with HBV DNA levels ≥4 log (IU/mL) at baseline, a higher proportion of patients in the TDF + ETV group than the TDF group achieved a virologic response (92.9% vs 68.3%; P<.001), while 90% of patients with HBV DNA (IU/mL) levels <4 log in all both TDF and TDF + ETV groups achieved a virologic response. TDF mono-rescue therapy is a reasonable option in patients with lamivudine resistance and entecavir resistance. However, the combination strategy should be considered in patients with high baseline HBV DNA levels.Scopus© Citations 24
